MX2022011188A - Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo. - Google Patents

Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo.

Info

Publication number
MX2022011188A
MX2022011188A MX2022011188A MX2022011188A MX2022011188A MX 2022011188 A MX2022011188 A MX 2022011188A MX 2022011188 A MX2022011188 A MX 2022011188A MX 2022011188 A MX2022011188 A MX 2022011188A MX 2022011188 A MX2022011188 A MX 2022011188A
Authority
MX
Mexico
Prior art keywords
preparation
method therefor
fused bicyclic
pharmaceutical use
bicyclic derivative
Prior art date
Application number
MX2022011188A
Other languages
English (en)
Inventor
Yang Chen
Feng He
Weikang Tao
Xin Li
Zhigao Zhang
Zhihao Li
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2022011188A publication Critical patent/MX2022011188A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

Un derivado bicíclico fusionado se muestra en la fórmula general (I), un método de preparación, por lo tanto, una composición farmacéutica que comprende el derivado y un uso del mismo como agente terapéutico, particularmente el uso del mismo como un inhibidor de AKT1/2/3 (AKT pan). y el uso en la preparación de un medicamento para tratar y/o prevenir tumores. Cada grupo en la fórmula general (I) es como se define en la descripción.
MX2022011188A 2020-03-17 2021-03-16 Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo. MX2022011188A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN202010185224 2020-03-17
CN202010418453 2020-05-18
CN202110241159 2021-03-04
PCT/CN2021/081033 WO2021185238A1 (zh) 2020-03-17 2021-03-16 稠合二环类衍生物、其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
MX2022011188A true MX2022011188A (es) 2022-11-08

Family

ID=77770759

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011188A MX2022011188A (es) 2020-03-17 2021-03-16 Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo.

Country Status (11)

Country Link
US (1) US20230148417A1 (es)
EP (1) EP4122922A4 (es)
JP (1) JP2023520140A (es)
KR (1) KR20220154722A (es)
CN (1) CN115397815A (es)
AU (1) AU2021238799A1 (es)
BR (1) BR112022017856A2 (es)
CA (1) CA3167999A1 (es)
MX (1) MX2022011188A (es)
TW (1) TW202136269A (es)
WO (1) WO2021185238A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202328138A (zh) * 2021-09-17 2023-07-16 大陸商江蘇恒瑞醫藥股份有限公司 稠合二環類衍生物的可藥用鹽、晶型及其製備方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994172B2 (en) 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
GB2450522B (en) 2007-06-29 2011-12-07 Motorola Inc Method and apparatus for determining beamforming weights for an antenna array
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5635910B2 (ja) 2008-01-09 2014-12-03 アレイ バイオファーマ、インコーポレイテッド ＡＫＴタンパク質キナーゼ阻害剤としての５Ｈ−シクロペンタ［ｄ］ピリミジン
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
CN102574857B (zh) * 2009-07-08 2015-06-10 利奥制药有限公司 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物
NO2721710T3 (es) * 2014-08-21 2018-03-31
JP6929286B2 (ja) * 2015-12-18 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 治療用化合物、組成物及びその使用方法
JOP20180094A1 (ar) * 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز

Also Published As

Publication number Publication date
EP4122922A1 (en) 2023-01-25
EP4122922A4 (en) 2023-08-23
JP2023520140A (ja) 2023-05-16
WO2021185238A1 (zh) 2021-09-23
CN115397815A (zh) 2022-11-25
BR112022017856A2 (pt) 2022-11-01
AU2021238799A1 (en) 2022-09-22
KR20220154722A (ko) 2022-11-22
TW202136269A (zh) 2021-10-01
US20230148417A1 (en) 2023-05-11
CA3167999A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
BR0312933A (pt) Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MY127369A (en) Quinazoline derivatives
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
BR0315580A (pt) Derivados de metileno uréia
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
IL151628A0 (en) Combination therapies with vascular damaging activity
CR20220537A (es) [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
IL163951A0 (en) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ZA202308118B (en) Cdk inhibitor
MX2022011188A (es) Derivado biciclico fusionado, metodo de preparacion y uso farmaceutico del mismo.
BR0114276A (pt) Derivados de benzodiazepina ou sais destes farmaceuticamente aceitáveis, agente para inibir o fator x de coagulação do sangue ativado, composição farmacêutica, e, inibidor da coagulação sanguìnea ou um agente para prevenir ou tratar a trombose ou o embolismo
MX9800620A (es) (r)-5-bromo-n-(1-etil-4-metilhexahidro-1h-1,4-diazepin-6-il- 2-metoxi-6-metilamino-3-piridincarboxamida, proceso para preparacion del mismo y composicion farmaceutica que contiene tal compuesto.
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents